DE3907290A1 - STEROID HORMONE RECEPTOR AFFINES ANTITUARY ACTIVE SUBSTANCES - Google Patents
STEROID HORMONE RECEPTOR AFFINES ANTITUARY ACTIVE SUBSTANCESInfo
- Publication number
- DE3907290A1 DE3907290A1 DE19893907290 DE3907290A DE3907290A1 DE 3907290 A1 DE3907290 A1 DE 3907290A1 DE 19893907290 DE19893907290 DE 19893907290 DE 3907290 A DE3907290 A DE 3907290A DE 3907290 A1 DE3907290 A1 DE 3907290A1
- Authority
- DE
- Germany
- Prior art keywords
- amino
- cytostatic
- dichloromethane
- mmol
- conjugates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000005969 steroid hormone receptors Human genes 0.000 title claims abstract description 5
- 108020003113 steroid hormone receptors Proteins 0.000 title claims abstract description 4
- 239000013543 active substance Substances 0.000 title 1
- 239000000824 cytostatic agent Substances 0.000 claims abstract description 11
- 230000001085 cytostatic effect Effects 0.000 claims abstract description 11
- 150000001408 amides Chemical class 0.000 claims abstract description 5
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 3
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 3
- 229910052751 metal Inorganic materials 0.000 claims abstract description 3
- 239000002184 metal Substances 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims abstract 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract 2
- -1 2- [4- (1,2-diphenyl-1-butenyl) phenoxy] phenylamine Chemical class 0.000 claims description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 14
- 239000000741 silica gel Substances 0.000 claims description 14
- 229910002027 silica gel Inorganic materials 0.000 claims description 14
- 238000004440 column chromatography Methods 0.000 claims description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 12
- 150000003431 steroids Chemical class 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 150000003628 tricarboxylic acids Chemical class 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 150000001413 amino acids Chemical group 0.000 claims description 5
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 230000003637 steroidlike Effects 0.000 claims description 5
- QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 claims description 4
- 102000015636 Oligopeptides Human genes 0.000 claims description 4
- 108010038807 Oligopeptides Proteins 0.000 claims description 4
- 230000032050 esterification Effects 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 3
- 230000009435 amidation Effects 0.000 claims description 3
- 238000007112 amidation reaction Methods 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- GRXPVLPQNMUNNX-MHJRRCNVSA-N estrane Chemical compound C1CC2CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 GRXPVLPQNMUNNX-MHJRRCNVSA-N 0.000 claims description 3
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 claims description 3
- 239000011877 solvent mixture Substances 0.000 claims description 3
- 239000003270 steroid hormone Substances 0.000 claims description 3
- 150000000000 tetracarboxylic acids Chemical class 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 2
- 150000001371 alpha-amino acids Chemical class 0.000 claims description 2
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- JWMFYGXQPXQEEM-WZBAXQLOSA-N pregnane Chemical class C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC)[C@@]1(C)CC2 JWMFYGXQPXQEEM-WZBAXQLOSA-N 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 239000003791 organic solvent mixture Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 1
- 239000002295 alkylating antineoplastic agent Substances 0.000 claims 1
- 230000002862 amidating effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 4
- 230000000118 anti-neoplastic effect Effects 0.000 abstract description 2
- 108010085012 Steroid Receptors Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 235000013311 vegetables Nutrition 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 131
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- 238000000921 elemental analysis Methods 0.000 description 14
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000004809 thin layer chromatography Methods 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical class [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- YJZJEQBSODVMTH-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2-hydroxyethyl)-1-nitrosourea Chemical compound OCCNC(=O)N(N=O)CCCl YJZJEQBSODVMTH-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000001819 mass spectrum Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 238000002211 ultraviolet spectrum Methods 0.000 description 6
- 229960004719 nandrolone Drugs 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 4
- JKMILVOVUWCVPG-UHFFFAOYSA-N n',n'-bis(2-chloroethyl)ethane-1,2-diamine Chemical compound NCCN(CCCl)CCCl JKMILVOVUWCVPG-UHFFFAOYSA-N 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000012261 resinous substance Substances 0.000 description 4
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- MCJKBWHDNUSJLW-UHFFFAOYSA-N 2-[4-(1,2-diphenylbut-1-enyl)phenoxy]ethanamine Chemical class C=1C=CC=CC=1C(CC)=C(C=1C=CC(OCCN)=CC=1)C1=CC=CC=C1 MCJKBWHDNUSJLW-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229940009456 adriamycin Drugs 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 229960004630 chlorambucil Drugs 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- RHQQHZQUAMFINJ-GKWSUJDHSA-N 1-[(3s,5s,8s,9s,10s,11s,13s,14s,17s)-3,11-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-hydroxyethanone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CC[C@H]21 RHQQHZQUAMFINJ-GKWSUJDHSA-N 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 239000011345 viscous material Substances 0.000 description 2
- FBMXBXAYQCWEOC-PNKHAZJDSA-N (8r,9s,10r,13s,14s)-13-methyl-1,2,3,6,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene Chemical compound C1CC2=CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 FBMXBXAYQCWEOC-PNKHAZJDSA-N 0.000 description 1
- BOLMNLJKDBCJIB-CUFSGNDSSA-N (8r,9s,13s,14s,17s)-13-methyl-3-(oxan-2-yloxy)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-ol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC1CCCCO1 BOLMNLJKDBCJIB-CUFSGNDSSA-N 0.000 description 1
- MPQOWLNEPUIIBZ-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-1,2,3,6,7,8,14,15,16,17-decahydrocyclopenta[a]phenanthrene Chemical compound C1CC2=CCCCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)C=C2 MPQOWLNEPUIIBZ-SQNIBIBYSA-N 0.000 description 1
- LGTNVTBMTQCJMS-BYZMTCBYSA-N (8s,9s,10r,13r,14s,17s)-17-ethyl-10,13-dimethyl-2,3,8,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1=CC2=CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC)[C@@]1(C)CC2 LGTNVTBMTQCJMS-BYZMTCBYSA-N 0.000 description 1
- SBNLPRGISFUZQE-VMXHOPILSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1C=C2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 SBNLPRGISFUZQE-VMXHOPILSA-N 0.000 description 1
- IATKKATWPOVYCC-VMXHOPILSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CC2=CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 IATKKATWPOVYCC-VMXHOPILSA-N 0.000 description 1
- JMYVDDWUJYTUEY-BDXSIMOUSA-N (8s,9s,13s,14s)-13-methyl-1,2,3,4,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene Chemical compound C([C@H]1[C@@H]2CCC[C@]2(CC[C@@H]11)C)CC2=C1CCCC2 JMYVDDWUJYTUEY-BDXSIMOUSA-N 0.000 description 1
- HLCRYAZDZCJZFG-BDXSIMOUSA-N (8s,9s,13s,14s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene Chemical compound C1CC2=CC=CC=C2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 HLCRYAZDZCJZFG-BDXSIMOUSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- FFGSXKJJVBXWCY-UHFFFAOYSA-N 1,4-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO FFGSXKJJVBXWCY-UHFFFAOYSA-N 0.000 description 1
- NZEYWBNQKCRBFO-UHFFFAOYSA-N 2-acetamido-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound CC(=O)NC(C(O)=O)CC1=CC=C(N(CCCl)CCCl)C=C1 NZEYWBNQKCRBFO-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- IBOGTICPYNDHHQ-UHFFFAOYSA-N 4-[1-[4-[2-(2-aminoethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol Chemical compound C=1C=CC=CC=1C(CC)=C(C=1C=CC(OCCNCCN)=CC=1)C1=CC=C(O)C=C1 IBOGTICPYNDHHQ-UHFFFAOYSA-N 0.000 description 1
- QSTBDQQOGIXUHJ-UHFFFAOYSA-N 4-[1-[4-[2-(6-aminohexylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol Chemical compound C=1C=CC=CC=1C(CC)=C(C=1C=CC(OCCNCCCCCCN)=CC=1)C1=CC=C(O)C=C1 QSTBDQQOGIXUHJ-UHFFFAOYSA-N 0.000 description 1
- JJPWJEGNCRGGGA-UHFFFAOYSA-N 4-[[2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]acetyl]amino]benzoic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)NC1=CC=C(C(=O)O)C=C1 JJPWJEGNCRGGGA-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- DEUFOCBRSCRPCX-NRBHBUSZSA-N C1C[C@H]2CC[C@H]3[C@@H](CCC4CCCC[C@H]34)[C@@H]2C1.[C@@H]12CC[C@H](CC)[C@@]1(C)CC[C@H]1[C@H]2CCC2CCCC[C@]12C Chemical class C1C[C@H]2CC[C@H]3[C@@H](CCC4CCCC[C@H]34)[C@@H]2C1.[C@@H]12CC[C@H](CC)[C@@]1(C)CC[C@H]1[C@H]2CCC2CCCC[C@]12C DEUFOCBRSCRPCX-NRBHBUSZSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 229910020427 K2PtCl4 Inorganic materials 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-Tyrosine Natural products OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-UHFFFAOYSA-N Merphalan Chemical compound OC(=O)C(N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-UHFFFAOYSA-N 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- BHPOSOPTQVNCFN-UHFFFAOYSA-N OC1=CC=C(C=2C(C3=C(C=CC(=C3C(C12)=O)NCCNCCO)NCCNCCO)=O)O.C1(C(C=CC2=CC3=CC=CC=C3C=C12)=O)=O Chemical compound OC1=CC=C(C=2C(C3=C(C=CC(=C3C(C12)=O)NCCNCCO)NCCNCCO)=O)O.C1(C(C=CC2=CC3=CC=CC=C3C=C12)=O)=O BHPOSOPTQVNCFN-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 241001620634 Roger Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229950011363 ametantrone Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003100 antineoplastic metal complex Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GLZNEMWJNDMRFW-UHFFFAOYSA-N bis(2-chloroethyl)aminophosphonic acid dihydrochloride Chemical compound Cl.Cl.ClCCN(P(O)(=O)O)CCCl GLZNEMWJNDMRFW-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- RJXQSIKBGKVNRT-UHFFFAOYSA-N phosphoramide mustard Chemical class ClCCN(P(O)(=O)N)CCCl RJXQSIKBGKVNRT-UHFFFAOYSA-N 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 229920000833 poly(n-hexyl isocyanate) polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000009419 refurbishment Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/66—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to halogen atoms or to nitro or nitroso groups
- C07C275/68—N-nitroso ureas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Zytostatika, die klinisch zur Behandlung maligner Tumoren eingesetzt werden, weisen häufig schwerwiegende Toxizität, insbesondere Myelotoxizität, Hepatoxizität, Nephrotoxizität und Lungentoxizität auf, die dosislimitierende Faktoren darstellen und die klinische Effektivität begrenzen (Eisenbrand G. et al: in Experimental und clinical chemotherapy, Vol. III, Georg Thieme Verlag, 1984, 35-91).Cytostatics that are used clinically to treat malignant tumors often have serious toxicity, especially myelotoxicity, hepatoxicity, nephrotoxicity and lung toxicity, the dose limiting factors represent and limit clinical effectiveness (Eisenbrand G. et al: in Experimental and clinical chemotherapy, Vol. III, Georg Thieme Verlag, 1984, 35-91).
Zahlreiche menschliche Tumoren, vor allem Mammacarcinome, Prostatacarcinome, bestimmte Gastrointestinaltumoren und bestimmte Hirntumoren enthalten Hormonrezeptoren. Dies bietet die Möglichkeit einer gezielten Therapie durch Verknüpfung von Zytostatika mit rezeptoraffinen Trägern.Numerous human tumors, especially breast cancer, Prostate carcinomas, certain gastrointestinal tumors and certain brain tumors contain hormone receptors. This offers the possibility of targeted therapy Linking cytostatics with receptor-affine carriers.
Aufgabe der Erfindung sind demnach Verbindungen, welche durch diese Verknüpfung eine Anreicherung im Tumorgewebe erreichen, was eine Erhöhung der tumorspezifischen Wirkung und eine Verringerung der systemischen Toxizitäten mit sich bringen sollte.The object of the invention is therefore compounds which through this connection, an accumulation in the tumor tissue achieve what an increase in tumor-specific effect and a reduction in systemic toxicities should bring.
Gegenstand der vorliegenden Patentanmeldung sind Zytostatikakonjugate mit solchen Trägermolekülen, die eine Bindungsaffinität zu Steroidhormonrezeptoren aufweisen. Die Verknüpfung von Zytostatika und Trägern erfolgt über geeignete Verbindungselemente, wobei in der Regel Amid- oder Esterbindungen geknüpft werden.The subject of the present patent application are Cytostatic conjugates with such carrier molecules that a Have binding affinity for steroid hormone receptors. The The cytostatics and carriers are linked via suitable fasteners, usually amide or Ester bonds are made.
L-Lost-Derivate und N-(2-Chlorethyl)-N-nitrosoharnstoffe sind Alkylantien. Einige Vertreter sind klinisch etablierte Antineoplastika. Weitere zeigen ausgeprägte antineoplastische Aktivität in experimentellen Untersuchungen. Chlorambucil, Mephalan bzw. Acetylmelphalen, N,N-Bis(2-Chlorethyl)-phosphorsäurediamid und N-[N-(2-Chlorethyl)-N-nitrosocarbamyl]aminosäuren oder -oligopeptide besitzen eine freie Säuregruppe, die zur Verknüpfung über ein Verbindungselement mit Trägermolekülen ausgenutzt werden kann. N-(2-Chlorethyl)-N′-(2-hydroxyethyl)-N-nitrosoharnstoff und N,N-Bis-(2-Chlorethyl)-aminoethylamin lassen sich über Hydroxyl- bzw. Aminogruppe verknüpfen.L-mustard derivatives and N- (2-chloroethyl) -N-nitrosoureas are alkylating agents. Some representatives are clinically established Antineoplastic agents. Others show pronounced antineoplastic activity in experimental Investigations. Chlorambucil, mephalan or acetylmelphalen, N, N-bis (2-chloroethyl) phosphoric acid diamide and N- [N- (2-chloroethyl) -N-nitrosocarbamyl] amino acids or -oligopeptides have a free acid group which is responsible for Linking via a connecting element with carrier molecules can be exploited. N- (2-chloroethyl) -N '- (2-hydroxyethyl) -N-nitrosourea and N, N-bis (2-chloroethyl) aminoethylamine can be Link hydroxyl or amino group.
Die Verknüpfung von antineoplastischen Antibiotika, wie Mitomycin, Adriamycin, Daunomycin, Epirubicin, sowie Anthracendionderivate wie Mitoxantron und Amethantron wird über eine Amino- oder Hydroxylgruppe vorgenommen. Antineoplastische Metallkomplexe wie z. B. (1,2-diominoethan)-cis-dichloroplatin (II) werden über ein geeignetes Verbindungselement z. B. COOH oder -OH an das Trägermolekül gebunden. Als rezeptoraffine Träger dienen Steroide einerseits und nichtsteroidale steroidhormonrezeptoraffine Verbindungen andererseits. Der Ausdruck Steroid umfaßt Verbindungen mit dem Grundgerüst der Estran-, Androstan und Pregnanreihe. Nicht steroidale rezeptoraffine Verbindungen sind vorzugsweise solche aus der Reihe der 2-[4-(1,2-diphenyl-1-butenyl)-phenoxy]-ethylamine.Linking antineoplastic antibiotics, such as Mitomycin, Adriamycin, Daunomycin, Epirubicin, as well Anthracenedione derivatives such as mitoxantrone and amethantrone will made via an amino or hydroxyl group. Antineoplastic metal complexes such as B. (1,2-diominoethane) -cis-dichloroplatin (II) are about one suitable connector z. B. COOH or -OH to that Carrier molecule bound. Serve as receptor-affine carriers Steroids on the one hand and non-steroidal ones steroid hormone receptor-affine compounds on the other hand. The The term steroid encompasses connections with the basic framework of Estran, Androstan and Pregnan range. Not steroidal receptor-affine compounds are preferably those from the Series of 2- [4- (1,2-diphenyl-1-butenyl) phenoxy] ethylamines.
Im folgenden werden bevorzugte Ausgangsmaterialien, Träger und Verbindungselemente zwischen Träger und Antitumorwirkstoff gezeigt:The following are preferred starting materials, carriers and connecting elements between the carrier and Antitumor drug shown:
1. Unter Antitumorwirkstoffen werden folgende klinisch etablierten bzw. experimentell hochwirksamen Verbindungen verstanden: 1. Among anti-tumor agents, the following are clinical established or experimentally highly effective compounds Roger that:
Lost-Derivate
- 4-[Bis(2-chlorethyl)amino]-phenylbuttersäure
(Chlorambucil) (1)
- 4-[Bis(2-chlorethyl)amino]-L-phenylalanin (Melphalan) (2)
- 4-[Bis(2-chlorethyl)amino]-N-acetyl-L-phenylalanin
(Acetylmelphalan) (3)
- N,N-Bis(2-chlorethyl)aminoethylamin (Mustamin) (4)
- N,N-Bis(2-chlorethyl)-phosphorsäurediamid (5)Lost derivatives
- 4- [bis (2-chloroethyl) amino] phenylbutyric acid (chlorambucil) (1)
- 4- [bis (2-chloroethyl) amino] -L-phenylalanine (melphalan) (2)
- 4- [bis (2-chloroethyl) amino] -N-acetyl-L-phenylalanine (acetylmelphalan) (3)
- N, N-bis (2-chloroethyl) aminoethylamine (mustamine) (4)
- N, N-bis (2-chloroethyl) phosphoric acid diamide (5)
CNC-Derivate
- N-(2-Chlorethyl)-N′-(2-hydroxyethyl)-N-nitrosoharnstoff
(HECNU) (6)
- N-[2-(2-Chlorethyl)-N-nitrosocarbamoyl]-aminosäure (7)
oder oligopeptide (8) (CNC-aminosäuren, CNC-oligopeptide)CNC derivatives
- N- (2-chloroethyl) -N ′ - (2-hydroxyethyl) -N-nitrosourea (HECNU) (6)
- N- [2- (2-chloroethyl) -N-nitrosocarbamoyl] amino acid (7) or oligopeptide (8) (CNC amino acids, CNC oligopeptides)
Antitumor Antibiotica
- Adriamycin (9)
- Daunomycin (10)
- Epirubicin (11)
- Idarubicin (12)
- Esorubicin (13)
- Aclarubicin (14)
- Carubicin (15)
- Mitomycin (16)
- Bleomycin (17)Antitumor antibiotics
- Adriamycin (9)
- Daunomycin (10)
- epirubicin (11)
- Idarubicin (12)
- Esorubicin (13)
- aclarubicin (14)
- Carubicin (15)
- Mitomycin (16)
- bleomycin (17)
Anthracendione
- 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-
9,10-anthracendion (Metoxantron) (18)
- 5,8-Bis-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-antracendion
(Ametantron) (19)Anthracendione
- 1,4-dihydroxy-5,8-bis [[2 - [(2-hydroxyethyl) amino] ethyl] amino] - 9,10-anthracenedione (metoxantrone) (18)
- 5,8-bis - [[2 - [(2-hydroxyethyl) amino] ethyl] amino] -9,10-antracendione (ametantrone) (19)
Metallkomplexe
- N-Aminoalkyl-(1,2-diaminoethan)cis-dichloroplatin (II) (20)
- Carboplatin (21)
- PHIC (22)
- Hydroxy-DACH (23)
- CisPt(II)-Citrat
- CisPt(II)-Bisascorbat
- DACCP (24)Metal complexes
- N-aminoalkyl- (1,2-diaminoethane) cis-dichloroplatin (II) (20)
- carboplatin (21)
- PHIC (22)
- Hydroxy-ROOF (23)
- CisPt (II) citrate
- CisPt (II) bisascorbate
- DACCP (24)
Pflanzeninhaltsstoffe bzw. semisynthetische Derivate
- Vinblastin (25)
- Vincristin (26)
- Vindesin (27)
- Vinzolidin (28)
- Etoposid (VM26) (29)
- Teniposid (VP16) (30)Plant ingredients or semi-synthetic derivatives
- Vinblastine (25)
- Vincristine (26)
- Vindesin (27)
- Vinzolidin (28)
- etoposide (VM26) (29)
- teniposide (VP16) (30)
2. Als Träger dienen:
Steroide, vorzugsweise solche mit Grundgerüst aus der
Estran-, Androstan- oder Pregnan- (Gonan) -Reihe.
Vorzugsweise werden Hydroxygruppen-tragende Steroide
eingesetzt aus der Gruppe der Estra 1,3,5(10)triene,
Androstane, Androst-4-ene, Androst-5-ene, Estr-4-ene,
Estr-5(10)ene, Estra-4,9,11-triene, Pregn-4-ene,
Pregna-4,6-diene.2. Serve as carrier:
Steroids, preferably those with a basic structure from the Estran, Androstan or Pregnan (Gonan) series. Hydroxy-bearing steroids are preferably used from the group consisting of Estra 1,3,5 (10) triene, Androstane, Androst-4-ene, Androst-5-ene, Estr-4-ene, Estr-5 (10) ene, Estra-4,9,11-triene, Pregn-4-ene, Pregna-4,6-diene.
Vorzugsweise werden die Hydroxygruppe(n) in Position 11, 17 oder 21 verestert. Weiterhin werden nichtsteroidale steroidrezeptoraffine Verbindungen, vorzugsweise aus der Reihe der 2-[4-(1,2-diphenyl-1-butenyl)-phenoxy]ethylamine eingesetzt. The hydroxyl group (s) are preferably in position 11, 17 or 21 esterified. Furthermore, nonsteroidal steroid receptor-affine compounds, preferably from the Series of 2- [4- (1,2-diphenyl-1-butenyl) phenoxy] ethylamines used.
3. Als Verbindungselement zwischen Träger und
Antitumorwirkstoff werden vorzugsweise eingesetzt:
- Carboxalkylgruppen
HOOC-(CH₂) n -, n = 1-11
- Aminoalkylgruppen
NA₂(CH₂) n -, n = 1-12
- Aminoalkylcarbonsäuren
NH₂-(CH₂) n -COOH, n = 1-11
- ω-Carboxyalkyl-1-oxo-aminoalkylamine
NH₂-(CH₂) n -NH-CO-(CH₂) m -COOH, n = 1-11, m = 1-12
- ω-Carboxyalkyl-1-oxo-aminoalkylaminoalkylamin
NH₂-(CH₂) n -NH-(CH₂) n -NH-CO-(CH₂) m -COOH,
n = 1-11, m = 1-123. The following are preferably used as the connecting element between the carrier and the antitumor agent:
- Carboxalkyl groups HOOC- (CH₂) n -, n = 1-11
- Aminoalkyl groups NA₂ (CH₂) n -, n = 1-12
- Aminoalkyl carboxylic acids NH₂- (CH₂) n -COOH, n = 1-11
- ω- Carboxyalkyl-1-oxo-aminoalkylamines NH₂- (CH₂) n -NH-CO- (CH₂) m -COOH, n = 1-11, m = 1-12
- ω- Carboxyalkyl-1-oxo-aminoalkylaminoalkylamine NH₂- (CH₂) n -NH- (CH₂) n -NH-CO- (CH₂) m -COOH, n = 1-11, m = 1-12
Hydroxylierte Di- und Tricarbonsäuren
- Milchsäure
- Weinsäure
- Tartronsäure
- Apfelsäure
- CitronensäureHydroxylated di- and tricarboxylic acids
- lactic acid
- tartaric acid
- tartronic acid
- malic acid
- citric acid
Ethylendiamin-di-, tri- und tetracarbonsäure
Amino- oder Oligopeptide (bis Hexapeptid) aus identischen
oder unterschiedlichen Aminosäurebausteinen unter
vorzugsweiser Verwendung von folgenden alpha-Aminosäuren:
- Glycin
- Alanin
- Valin
- Leucin
- Isoleucin
- Methionin
- Sarkosin
- Prolin
- Hydroxyprolin
- Cystein
- Cystin
- Phenylalanin
- Tyrosin
- Tryptophan
- LysinEthylenediamine-di-, tri- and tetracarboxylic acid amino or oligopeptides (up to hexapeptide) from identical or different amino acid components, preferably using the following alpha-amino acids:
- glycine
- Alanine
- Valine
- Leucine
- isoleucine
- methionine
- Sarcosine
- Proline
- hydroxyproline
- cysteine
- cystine
- phenylalanine
- tyrosine
- tryptophan
- lysine
Tris-hydroxymethylaminomethan-monoester von hydroxylierter oder nicht hydroxylierten Dicarbonsäuren bzw. Ethylendiamin- di-, tri- oder tetracarbonsäure.Tris-hydroxymethylaminomethane monoester of hydroxylated or non-hydroxylated dicarboxylic acids or ethylenediamine di-, tri- or tetracarboxylic acid.
Die Herstellung der Konjugate erfolgt durch Verknüpfung von Verbindungselement einerseits mit dem Antitumorwirkstoff, andererseits mit dem steroidrezeptoraffinen Träger über eine Ester- oder eine Amid-Bindung.The conjugates are produced by linking Connecting element on the one hand with the antitumor agent, on the other hand with the steroid receptor-affine carrier via a Ester or an amide bond.
Die Veresterung erfolgt bevorzugt mit Carbonyldiimidazol oder Dicyclohexylcarbodiimid (DCC) mit oder ohne Zusatz von p-Dimethylaminopyridin (DMAP). Die Amidierung erfolgt mittels Dicyclohexylcarbodiimid oder Carbonyldiimidazol mit oder ohne Zusatz von p-Dimethylaminopyridin oder über einen aktiven N-Hydroxysuccinimid Ester bzw. über ein Azid der Säure.The esterification is preferably carried out using carbonyldiimidazole or dicyclohexylcarbodiimide (DCC) with or without the addition of p-dimethylaminopyridine (DMAP). The amidation takes place using dicyclohexylcarbodiimide or carbonyldiimidazole or without the addition of p-dimethylaminopyridine or via one active N-hydroxysuccinimide ester or via an azide Acid.
Die Veresterung bzw. Amidierung wird bei Raumtemperatur vorgenommen. Allgemein ist die Reaktionsdauer zwischen 1- 24 h, bei Zimmertemperatur oder etwas weniger bei leicht erhöhter Temperatur, z. B. 1-12 h.The esterification or amidation is carried out at room temperature performed. Generally the reaction time is between 1- 24 h, at room temperature or slightly less at light elevated temperature, e.g. B. 1-12 h.
Folgende Lösungsmittel werden bevorzugt verwendet:
n-Hexan, Dichlormethan, Chloroform, Ether, Aceton,
Tetrahydrofuran, Methanol, Ethanol, Acetonitril, bzw. deren
Gemische. Die Reindarstellung der Konjugate erfolgt entweder
säulenchromatographisch an geeigneten Adsorptionsmitteln,
bevorzugt an Kieselgel, eluiert mit geeignetem Lösungsmittel
oder Lösungsmittelgemisch, oder durch Umkristallisation.The following solvents are preferred:
n-Hexane, dichloromethane, chloroform, ether, acetone, tetrahydrofuran, methanol, ethanol, acetonitrile, or mixtures thereof. The conjugates are prepared in pure form either by column chromatography on suitable adsorbents, preferably on silica gel, eluted with a suitable solvent or solvent mixture, or by recrystallization.
Die folgenden Beispiele erläutern die Erfindung.The following examples illustrate the invention.
1,4 g (3 mmol) 17β-O-(Aminohexylamino-1,4-dioxo-butyl)estradiol und eine Spatelspitze 4-Dimethylaminopyridin werden in 20 ml Tetrahydrofuran (THF) gelöst und langsam wird eine Lösung von 1,05 g (3,6 mmol) N-(CNC-L-alanyloxy)-tetrahydropyrrol in 10 ml THF zugetropft. Nach 4 h versetzt man das Reaktionsgemisch mit 40 ml Dichlormethan und schüttelt je 3mal mit gesättigter NaHSO₄- und NaHCO₃-Lösung aus. Die Dichlormethanphase wird über Natriumsulfat getrocknet und unter Vakuum zur Trockne eingeengt. Das Rohprodukt wird durch Säulenchromatographie auf Kieselgel gereinigt. Elutionsmittel: Ether (Aceton 10 : 2. Weißes, amorphes Pulver, Ausbeute: 51%1.4 g (3 mmol) of 17 β -O- (aminohexylamino-1,4-dioxo-butyl) estradiol and a spatula tip of 4-dimethylaminopyridine are dissolved in 20 ml of tetrahydrofuran (THF) and slowly a solution of 1.05 g (3.6 mmol) N- (CNC-L-alanyloxy) tetrahydropyrrole in 10 ml THF was added dropwise. After 4 h, the reaction mixture is mixed with 40 ml of dichloromethane and shaken 3 times with saturated NaHSO₄ and NaHCO₃ solution. The dichloromethane phase is dried over sodium sulfate and concentrated to dryness in vacuo. The crude product is purified by column chromatography on silica gel. Eluent: ether (acetone 10: 2. White, amorphous powder, yield: 51%
Elementaranalyse
C₃₄H₅₀ClN₅O₇, MW 676,25 g/mol
Ber. (%): C 60,4, H 7,45, N 10,4,
Gef. (%): C 59,1, H 6,86, N 9,9;Elemental analysis
C₃₄H₅₀ClN₅O₇, MW 676.25 g / mol
Ber. (%): C 60.4, H 7.45, N 10.4,
Found (%): C 59.1, H 6.86, N 9.9;
¹H-NMR (in CDCl₃)
δ (ppm) 7,6 (d, 1H), 7,3-7,0 (m, 1H), 6,7-6,4 (m, 4H),
5,9 (t, 1H), 4,6 (m, 2H), 4,1 (t, 2H), 3,5 (t, 2H), 2,0 (d, 1H),
0,8 (s, 3H)
IR (KBr) cm-1: 3300, 2930, 2560, 1730, 1650, 1500, 1450,
1010, 735.
1 H-NMR (in CDCl₃) δ (ppm) 7.6 (d, 1H), 7.3-7.0 (m, 1H), 6.7-6.4 (m, 4H), 5.9 ( t, 1H), 4.6 (m, 2H), 4.1 (t, 2H), 3.5 (t, 2H), 2.0 (d, 1H), 0.8 (s, 3H)
IR (KBr) cm -1 : 3300, 2930, 2560, 1730, 1650, 1500, 1450, 1010, 735.
Die Darstellung von 17β-O-(CNC-L-alanylaminohexylamino-1,4-dioxo-butyl)-19-nortestosteron erfolgt analog zu Beispiel 1 unter Verwendung von 1,4 g (3 mmol) 17b-O-(Aminohexylamino-1,4-dioxo-butyl)-19-nortestosteron. Weißes, amorphes Pulver, Ausbeute: 37%17 β -O- (CNC-L-alanylaminohexylamino-1,4-dioxo-butyl) -19-nortestosterone is prepared analogously to Example 1 using 1.4 g (3 mmol) 17 b -O- (aminohexylamino -1,4-dioxo-butyl) -19-nortestosterone. White, amorphous powder, yield: 37%
Elementaranalyse
C₃₄H₅₂ClN₅O₇, MW 678,27 g/mol
Ber. (%): C 60,2, H 7,72, N 10,3,
Gef. (%): C 60,1, H 8,17, N 10,9;Elemental analysis
C₃₄H₅₂ClN₅O₇, MW 678.27 g / mol
Ber. (%): C 60.2, H 7.72, N 10.3,
Found (%): C 60.1, H 8.17, N 10.9;
¹H-NMR (in CDCl₃)
δ (ppm) 7,6 (d, 1H), 5,7 (s, 1H), 4,6 (m, 2H),
4,1 (t, 2H), 3,5 (m, 2H), 2,6 (d, 4H), 0,7 (s, 3H),
IR (KBr) cm-1: 3400, 2920, 2860, 1710, 1660, 1450, 735.1 H-NMR (in CDCl₃) δ (ppm) 7.6 (d, 1H), 5.7 (s, 1H), 4.6 (m, 2H), 4.1 (t, 2H), 3.5 (m, 2H), 2.6 (d, 4H), 0.7 (s, 3H),
IR (KBr) cm -1 : 3400, 2920, 2860, 1710, 1660, 1450, 735.
Man stellt den Estradiol-17-succinato-HECNU-ester-3-
tetrahydropyranolether her und spaltet die Schutzgruppe mit
p-Toluolsulfonsäure ab
Ansatz:
1,2 g Estradiol-3-tetrahydropyranylether
1,5 g HECNU-Hemisuccinat in 30 ml abs. THF
1,1 g DCC + 0,1 g DMAP
The estradiol-17-succinato-HECNU-ester-3-tetrahydropyranol ether is prepared and the protective group is split off with p-toluenesulfonic acid from the beginning:
1.2 g estradiol-3-tetrahydropyranyl ether
1.5 g HECNU hemisuccinate in 30 ml abs. THF
1.1 g DCC + 0.1 g DMAP
Nach ca. 30 sec entsteht ein weißer Niederschlag. Es wird noch 1 h bei Raumtemperatur gerührt. Dabei tritt deutliche Farbvertiefung von gelb nach rotbraun ein. Nach weiteren 3 h im Kühlschrank wird einrotiert, in Dichlormethan aufgenommen und mit Dichlormethan/THF - 50/1 über Kieselgel filtriert. DC (Dichlormethan/THF = 25/1): Rf = 0,62. Es wird in THF mit einer Spatelspitze p-Toluolsulfonsäuregel filtriert. Wenn die gelbe Verunreinigung die Säule verlassen hat, wird das gewünschte Produkt mit CH₂Cl₂/THF = 20/1 eluiert. Mehrmaliges Abrotieren mit Ether liefert schließlich in 63% Ausbeute einen hochviskosen gelben Stoff. DC (Dichlormethan/THF = 10/1): Rf = 0,72A white precipitate forms after approx. 30 sec. The mixture is stirred at room temperature for 1 h. The color deepens from yellow to reddish brown. After a further 3 h in the refrigerator, the mixture is concentrated using a rotary evaporator, taken up in dichloromethane and filtered through silica gel with dichloromethane / THF - 50/1. TLC (dichloromethane / THF = 25/1): R f = 0.62. It is filtered in THF with a spatula tip of p-toluenesulfonic acid gel. When the yellow impurity has left the column, the desired product is eluted with CH₂Cl₂ / THF = 20/1. Repeated spinning with ether finally gives a highly viscous yellow substance in 63% yield. TLC (dichloromethane / THF = 10/1): R f = 0.72
Elementaranalyse
C₂₇H₃₅ClN₃O₇, NW 549,0 g/mol
Ber. (%): C 59,1, H 6,43, N 7,7, Cl 6,5,
Gef. (%): C 58,9, H 6,67, N 7,5, Cl 6,7;Elemental analysis
C₂₇H₃₅ClN₃O₇, NW 549.0 g / mol
Ber. (%): C 59.1, H 6.43, N 7.7, Cl 6.5,
Found (%): C 58.9, H 6.67, N 7.5, Cl 6.7;
¹H-NMR (in d₆-DMSO)
δ (ppm) 9,01 (s, 1H), 8,92 (t, 1H), 7,15 (d, 1H),
6,61 (d, 1H), 6,50 (s, 1H), 4,73 (m, 1H),
4,20 (m, 4H), 3,72 (m, 4H), 2,80 (s, 4H),
1-2,4 (m), 0,88 (s, 3H)
IR (KBr) cm-1: 3405, 2970, 2933, 1732, 1532, 1499,
1448, 1350, 1286, 1248, 1164, 1083,
1008, 963.1 H-NMR (in d₆-DMSO)
δ (ppm) 9.01 (s, 1H), 8.92 (t, 1H), 7.15 (d, 1H), 6.61 (d, 1H), 6.50 (s, 1H), 4 , 73 (m, 1H), 4.20 (m, 4H), 3.72 (m, 4H), 2.80 (s, 4H), 1-2.4 (m), 0.88 (s, 3H)
IR (KBr) cm -1 : 3405, 2970, 2933, 1732, 1532, 1499, 1448, 1350, 1286, 1248, 1164, 1083, 1008, 963.
Die Darstellung von Beispiel 4 erfolgt analog zu Beispiel 3
mit dem Unterschied, daß das Steroidhormon keine
Schutzgruppe trägt.
Ansatz:
1,0 g Dihydrotestosteron
1,8 g HECNU-hemisuccinat
50 ml abs. THF
1,2 g DCC
0,1 g DMAP
Hellgelbes amorphes PulverExample 4 is presented analogously to example 3, with the difference that the steroid hormone does not carry a protective group.
Approach:
1.0 g dihydrotestosterone
1.8 g HECNU hemisuccinate
50 ml abs. THF
1.2 g DCC
0.1 g DMAP
Light yellow amorphous powder
Elementaranalyse
C₂₈H₄₂ClN₃O₇, MW 568,1 g/mol
Ber. (%): C 59,2, H 7,80, N 7,4, Cl 6,2,
Gef. (%): C 59,5, H 7,89, N 7,1, Cl 6,5;Elemental analysis
C₂₈H₄₂ClN₃O₇, MW 568.1 g / mol
Ber. (%): C 59.2, H 7.80, N 7.4, Cl 6.2,
Found (%): C 59.5, H 7.89, N 7.1, Cl 6.5;
Die Darstellung von Beispiel 5 erfolgt analog zu Beispiel 4.
Ansatz:
1,5 g (10 mmol) Testosteron
1,8 g (6 mmol) HECNU-hemisuccinat
50 ml abs. THF
1,2 g (6 mmol) DCC + 0,1 g DMAP
Reaktionsdauer: 8 h
DC (Dichlormethan/THF = 25/1): Rf = 0,26
Ausbeute: 1,6 g (56% d. Th.)
Hellgelber viskoser StoffExample 5 is presented analogously to example 4.
Approach:
1.5 g (10 mmol) testosterone
1.8 g (6 mmol) HECNU hemisuccinate
50 ml abs. THF
1.2 g (6 mmol) DCC + 0.1 g DMAP
Response time: 8 h
TLC (dichloromethane / THF = 25/1): R f = 0.26
Yield: 1.6 g (56% of theory)
Light yellow viscous fabric
Elementaranalyse
C₂₈H₄₀ClN₃O₇, MW 566,1 g/mol
Ber. (%): C 59,4, H 7,12, N 7,4,
Gef. (%): C 59,1, H 7,13, N 7,4;
¹H-NMR (in d₆-DMSO)
δ (ppm) 8,85 (t, 1H), 5,56 (s, 1H) 4,52 (m, 1H), 4,09 (m,
4H), 3,60 (m, 4H), 2,52 (s, 4H), 0,8-2,4 (m), 1,13 (s, 3H),
0,75 (s, 3H)
IR (KBr) cm-1: 3395, 2946, 1734, 1671, 1531, 1492, 1332,
1272, 1232, 1161, 1083, 1040, 1010, 962.Elemental analysis
C₂₈H₄₀ClN₃O₇, MW 566.1 g / mol
Ber. (%): C 59.4, H 7.12, N 7.4,
Found (%): C 59.1, H 7.13, N 7.4;
1 H-NMR (in d₆-DMSO)
δ (ppm) 8.85 (t, 1H), 5.56 (s, 1H) 4.52 (m, 1H), 4.09 (m, 4H), 3.60 (m, 4H), 2, 52 (s, 4H), 0.8-2.4 (m), 1.13 (s, 3H), 0.75 (s, 3H)
IR (KBr) cm -1 : 3395, 2946, 1734, 1671, 1531, 1492, 1332, 1272, 1232, 1161, 1083, 1040, 1010, 962.
Die Herstellung von Beispiel 6 erfolgt analog zu Beispiel 4.
Ansatz:
1,4 g (5 mmol) 19-Nortestosteron
1,8 g (6 mmol) HECNU-hemisuccinat
50 ml abs. THF
1,2 g (6 mmol) DCC + 0,1 DMAP
Reaktionsdauer: 6 Stunden
Aufarbeitung:
Chromatographie über SiO₂ mit Dichlormethan/THF - 50/1
ergibt eine viskose Masse.
Ausbeute: 1,4 g (52% d. Th.)
DC (Dichlormethan/THF = 25/1): Rf = 0,21Example 6 is prepared analogously to example 4.
Approach:
1.4 g (5 mmol) 19-nortestosterone
1.8 g (6 mmol) HECNU hemisuccinate
50 ml abs. THF
1.2 g (6 mmol) DCC + 0.1 DMAP
Response time: 6 hours
Refurbishment:
Chromatography on SiO₂ with dichloromethane / THF - 50/1 gives a viscous mass.
Yield: 1.4 g (52% of theory)
TLC (dichloromethane / THF = 25/1): R f = 0.21
Elementaranalyse
C₂₇H₃₈ClN₃O₇, MW 552,1 g/mol
Ber. (%): C 58,7, H 6,94, N 7,6,
Gef. (%): C 58,5, H 7,27, N 7,4;Elemental analysis
C₂₇H₃₈ClN₃O₇, MW 552.1 g / mol
Ber. (%): C 58.7, H 6.94, N 7.6,
Found (%): C 58.5, H 7.27, N 7.4;
Eine Lösung von 15 mmol (3,9 g)
N,N-Bis-(2-chlorethyl)-phosphorsäureamiddichlorid unter 15
mmol (5,57 g) N-tert.-Butyloxycarbonyl-L-Thyrosinbenzylester
in 45 ml trockenem Benzol wird am Rückfluß erhitzt und
tropfenweise über einen Zeitraum von 15 min mit einer Lösung
von 17 mmol (2,37 ml) trockenem Triethylamin in 15 ml
trockenem Benzol versetzt. Das Reaktionsgemisch wird weitere
3 h am Rückfluß gekocht. Nach Abkühlen auf Raumtemperatur
wird solange Ammoniakgas eingeleitet (ca. 15 min) bis das
Zwischenprodukt dünnschichtchromatographisch nicht mehr
nachgewiesen werden kann. Das ausgefallene Ammoniumchlorid
wird abgesaugt, das Filtrat eingeengt und der Rückstand an
Kieselgel säulenchromatographisch gereinigt.
Laufmittel: Ethylformiat
Ausbeute: 7,8 g (90%).A solution of 15 mmol (3.9 g) of N, N-bis (2-chloroethyl) phosphoric acid amide dichloride under 15 mmol (5.57 g) of N-tert-butyloxycarbonyl-L-thyrosine benzyl ester in 45 ml of dry benzene is on The mixture was heated to reflux and a solution of 17 mmol (2.37 ml) of dry triethylamine in 15 ml of dry benzene was added dropwise over a period of 15 min. The reaction mixture is refluxed for a further 3 h. After cooling to room temperature, ammonia gas is introduced (approx. 15 min) until the intermediate product can no longer be detected by thin layer chromatography. The precipitated ammonium chloride is filtered off with suction, the filtrate is concentrated and the residue is purified by column chromatography on silica gel.
Mobile solvent: ethyl formate
Yield: 7.8 g (90%).
15 mmol (8,62 g) O-[N,N-Bis-(2-chlorethyl)diamidophosphoryloxy]-N-tert.-butyloxy- carbonyl-L-Tyrosinbenzylester werden in 20 ml absolutem Ethanol gelöst und mit einer Spatelspitze Palladium/Kohlenstoff-Katalysator versetzt. Die anschließende Hydrogenolyse bei Normaldruck wird solange durchgeführt, bis der Wasserstoffverbrauch beendet ist (ca. 1 h). Nach Filtration wird die ethanolische Lösung zur Trockene eingeengt. Durch mehrmaliges Behandeln mit trockenem Diethylether erhält man einen farblosen Schaum. Ausbeute: 7,05 g (97%)15 mmol (8.62 g) O- [N, N-bis (2-chloroethyl) diamidophosphoryloxy] -N-tert-butyloxy- carbonyl-L-tyrosine benzyl esters are in 20 ml absolute Dissolved ethanol and with a spatula tip Palladium / carbon catalyst added. The subsequent hydrogenolysis at normal pressure is as long carried out until the hydrogen consumption has ended (approx. 1 h). After filtration, the ethanolic solution becomes Dry evaporated. By repeated treatment with dry diethyl ether gives a colorless foam. Yield: 7.05 g (97%)
4 mmol (1,94 g) O-[N,N-Bis-(2-chlorethyl)diamidophosphoryloxy]-N-tert.-butyloxycarbo-nyl- L-Tyrosin werden in 30 ml Dichlormethan gelöst und mit 4,4 mmol (713 mg) Carbonyldiimidazol versetzt. Nach Beendigung der Gasentwicklung wird die Reaktionslösung 20 min im Ultraschallbad behandelt. Nach Zugabe von 4 ml des Steroidalkohols wird das Reaktionsgemisch nochmals 30 min beschallt und anschließend 2 Tage bei Raumtemperatur gerührt. Nach Entfernen des Lösungsmittels wird der Rückstand säulenchromatographisch aufgearbeitet (an Kieselgel). Die Produkte werden als farblose Schäume isoliert.4 mmol (1.94 g) O- [N, N-bis- (2-chloroethyl) diamidophosphoryloxy] -N-tert-butyloxycarbonyl- L-tyrosine are dissolved in 30 ml dichloromethane and 4.4 mmol (713 mg) of carbonyldiimidazole were added. To End of gas evolution, the reaction solution is 20 min treated in an ultrasonic bath. After adding 4 ml of the Steroidal alcohol, the reaction mixture is again 30 min sonicated and then 2 days at room temperature touched. After removing the solvent The residue was worked up by column chromatography (on Silica gel). The products are called colorless foams isolated.
5 mmol
O-[N,N-Bis-(2-chlorethyl)diamidophosphoryloxy]-N-tert.-butyloxycarbo-nyl-
L-tyrosin-steroid-17β-ester werden unter Eiskühlung
mit 12 ml 0,2 N Salzsäure in Eisessig versetzt und ca. 1 h
gerührt (DC-Kontrolle). Die Lösung wird zur Trockne
eingeengt, der Rückstand in 2 ml Methanol aufgenommen und
tropfenweise unter Rühren in 1 l Diethylether eingetragen.
Das Produkt fällt flockig weiß aus. Nach dem Abfritten wird
das farblose Pulver noch 2mal mit Diethylether gewaschen und
anschließend im Hochvakuum getrocknet.
Ausbeute: 50-70%.
Auf diese Weise wurden die folgenden Verbindungen
hergestellt.5 mmol of O- [N, N-bis (2-chloroethyl) diamidophosphoryloxy] -N-tert-butyloxycarbo-nyl-L-tyrosine-steroid-17 β- ester are dissolved in with ice cooling with 12 ml of 0.2 N hydrochloric acid Glacial acetic acid was added and the mixture was stirred for about 1 h (TLC control). The solution is evaporated to dryness, the residue is taken up in 2 ml of methanol and added dropwise to 1 l of diethyl ether while stirring. The product is flaky white. After frying, the colorless powder is washed twice with diethyl ether and then dried under high vacuum.
Yield: 50-70%.
In this way the following connections were made.
O-[N,N-Bis-(2-chlorethyl)diamidophosphoryloxy]-L-tyrosin-dihydrotest-osteron- 17β-ester hydrochloridO- [N, N-bis (2-chloroethyl) diamidophosphoryloxy] -L-tyrosine dihydrotest osteron--17 β -ester hydrochloride
Elementaranalyse
C₃₂H₄₉Cl₃N₃O₅P, MW 693,1 g/mol
Ber. (%): C 55,4, H 7,13, N 6,0,
Gef. (%): C 55,1, H 7,00, N 6,2;
IR (KBr) cm-1: 2950-2800, 1730, 1700, 1500, 1220.
O-[N,N-Bis-(2-chlorethyl)diamidophosphoryloxy]-L-tyrosin-
estradiol-17β-ester hydrochloridElemental analysis
C₃₂H₄₉Cl₃N₃O₅P, MW 693.1 g / mol
Ber. (%): C 55.4, H 7.13, N 6.0,
Found (%): C 55.1, H 7.00, N 6.2;
IR (KBr) cm -1 : 2950-2800, 1730, 1700, 1500, 1220.
O- [N, N-bis (2-chloroethyl) diamidophosphoryloxy] -L-tyrosine estradiol-17 β- ester hydrochloride
Elementaranalyse:
C₃₁H₄₃Cl₂N₃O₅P, MW 675,03 g/mol
Ber. (%): C 55,1, H 6,42, N 6,2,
Gef. (%): C 55,1, H 6,42, N 5,9;
¹H-NMR (in CD₃OD)
δ (ppm): 7,3 (s, 4H), 6,4-7,2 (m, 3H), 4,8 (t, 1H),
4,3 (m, 1H), 3,0-4,0 (m, 12H), 1,0-3,0 (m, 15H),
0,72 (s, 3H)
O-[N,N-Bis-(2-chlorethyl)-diamidophoshoryloxy]-L-tyrosin-19-
nortestosteron-17β-ester hydrochloridElemental analysis:
C₃₁H₄₃Cl₂N₃O₅P, MW 675.03 g / mol
Ber. (%): C 55.1, H 6.42, N 6.2,
Found (%): C 55.1, H 6.42, N 5.9;
1 H-NMR (in CD₃OD)
δ (ppm): 7.3 (s, 4H), 6.4-7.2 (m, 3H), 4.8 (t, 1H), 4.3 (m, 1H), 3.0-4 , 0 (m, 12H), 1.0-3.0 (m, 15H), 0.72 (s, 3H)
O- [N, N-bis (2-chloroethyl) -diamidophoshoryloxy] -L-tyrosine-19-nortestosterone-17 β -ester hydrochloride
Elementaranalyse
C₃₁H₄₅Cl₂N₃O₅P, MW 677,05 g/mol
Ber. (%): C 54,6, H 6,65, N 6,2,
Gef. (%): C 53,6, H 6,53, N 6,2;
¹H-NMR (in CD₃OD)
δ (ppm): 7,29 (s, 4H), 5,8 (s, 1H), 4,32 (d, 1H), 4,0-3,2
(m, 12H), 2,4-1,1 (m, 22H), 0,82 (s, 3H)Elemental analysis
C₃₁H₄₅Cl₂N₃O₅P, MW 677.05 g / mol
Ber. (%): C 54.6, H 6.65, N 6.2,
Found (%): C 53.6, H 6.53, N 6.2;
1 H-NMR (in CD₃OD)
δ (ppm): 7.29 (s, 4H), 5.8 (s, 1H), 4.32 (d, 1H), 4.0-3.2 (m, 12H), 2.4-1 , 1 (m, 22H), 0.82 (s, 3H)
In einem typischen Ansatz wurden 32 mg
Adriamycin-Hydrochlorid (0,055 mmol) in 12 ml absolutem
Dimethylformamid suspendiert. Zur Freisetzung der
Aminogruppe wurden 7 µl absolutes Triethylamin zugesetzt.
Anschließend wurde die Reaktionsmischung in
Stickstoff-Atmosphäre mit einer Lösung von 174 mg
DHT-Succ-Ala-Leu-N-Hydroxysuccinimidester in 3 ml
Dimethylformamid versetzt. Da nach DC-Abschätzung nach 12 h
nur ca. halber Umsatz zu erkennen war, wurden nochmals
4 µl Triethylamin zugespritzt. Nach insgesamt 2 h wurde in
Chloroform aufgenommen und mehrfach mit dest. Wasser
extrahiert. Die wäßrigen Phasen wurden mit Chloroform
reextrahiert. Nach Abziehen des Chloroforms am
Rotationsverdampfer wurde das zurückbleibende
Dimethylformamid im Ölpumpenvakuum bei Raumtemperatur
abgezogen. Der Rückstand wurde mehrfach über eine
Kieselgel-60-Platte (20 × 20 cm) (Chloroform/Methanol 15 : 1)
chromatographiert. Es wurden 43 mg (70% DC-reine rotorange
Substanz erhalten.
Rf-Wert (Chloroform/Methanol 9 : 1) 0,32
Massenspektrum (FAB): Molpeak m/c 1100
¹H-NMR (in CDCl₃)
δ (ppm): 13,98 (s, 1H), 13,28 (s, 1H), 8,07 (d, 1H), 7,80
(t, 1H), 7,40 (d, 1H), 7,05 (d, 1H), 6,68 (d, 1H), 6,12 (d,
1H), 5,51 (d, 1H), 5,27 (m, 1H), 4,75 (d, 1H), 4,30 (m, 1H),
4,25 (m, 1H), 4,10 (m, 1H), 4,09 (s, 3H), 3,98 (m, 1H), 3,79
(m, 1H), 3,22 (d, 1H), 3,05 (m, 2H), 2,60 (m, 1H), 2,42 (m,
2H), 1,48 (d, 3H), 1,31 (d, 3H), 0,95 (d, 3H), 0,90 (d, 3H),
0,78 (s, 3H), 0,62 (s, 3H)In a typical batch, 32 mg of adriamycin hydrochloride (0.055 mmol) was suspended in 12 ml of absolute dimethylformamide. 7 μl of absolute triethylamine were added to release the amino group. A solution of 174 mg of DHT-Succ-Ala-Leu-N-hydroxysuccinimide ester in 3 ml of dimethylformamide was then added to the reaction mixture in a nitrogen atmosphere. Since only about half of the conversion could be seen after 12 h according to the DC estimate, another 4 μl of triethylamine were injected. After a total of 2 h was taken up in chloroform and repeatedly with dist. Water extracted. The aqueous phases were re-extracted with chloroform. After the chloroform had been stripped off on a rotary evaporator, the remaining dimethylformamide was stripped off in an oil pump vacuum at room temperature. The residue was chromatographed several times on a silica gel 60 plate (20 × 20 cm) (chloroform / methanol 15: 1). 43 mg (70% DC-pure red-orange substance were obtained.
R f (chloroform / methanol 9: 1) 0.32
Mass spectrum (FAB): Molpeak m / c 1100
1 H-NMR (in CDCl₃)
δ (ppm): 13.98 (s, 1H), 13.28 (s, 1H), 8.07 (d, 1H), 7.80 (t, 1H), 7.40 (d, 1H), 7.05 (d, 1H), 6.68 (d, 1H), 6.12 (d, 1H), 5.51 (d, 1H), 5.27 (m, 1H), 4.75 (d , 1H), 4.30 (m, 1H), 4.25 (m, 1H), 4.10 (m, 1H), 4.09 (s, 3H), 3.98 (m, 1H), 3 , 79 (m, 1H), 3.22 (d, 1H), 3.05 (m, 2H), 2.60 (m, 1H), 2.42 (m, 2H), 1.48 (d, 3H), 1.31 (d, 3H), 0.95 (d, 3H), 0.90 (d, 3H), 0.78 (s, 3H), 0.62 (s, 3H)
5,5 g (12 mmol)
1-[4-(2-[6-aminohexyl]-aminoethoxy)-phenyl]-1-(4-hydroxyphenyl)-
2-phenyl-but-1-en, 12 mmol CNC-azid und 10 ml
Essigsäureanhydrid Säulenchromatographie über Kieselgel
(Dichlormethan/THF = 30 : 1/d = 4,5 cm; 1 = 60 cm).
Ausbeute: 1,7 g (21%) gelblichweißer, harziger, zähviskoser
Stoff
Rf-Wert (Dichlormethan/Ether/Petrolether = 1 : 1 : 1): 0,15
5.5 g (12 mmol) 1- [4- (2- [6-aminohexyl] aminoethoxy) phenyl] -1- (4-hydroxyphenyl) -2-phenyl-but-1-ene, 12 mmol CNC- azide and 10 ml acetic anhydride column chromatography on silica gel (dichloromethane / THF = 30: 1 / d = 4.5 cm; 1 = 60 cm).
Yield: 1.7 g (21%) of a yellowish white, resinous, viscous substance
R f value (dichloromethane / ether / petroleum ether = 1: 1: 1): 0.15
Elementaranalyse
C₃₇H₄₅ClN₄O₆, MW 677,26 g/mol
Ber. (%): C 65,6, H 6,69, N 8,3, Cl 5,2,
Gef. (%): C 65,6, H 6,89, N 8,1, Cl 5,4;
¹H-NMR (in CDCl₃)
δ (ppm) 7,3-6,41 (m, 13H), 4,25-3,9 (m, 4H), 3,8-3,3 (m, 8H),
2,48 (q, 2H), 2,33-2,21 (2a, 3H), 2,12-2,05 (2s, 3H)
1,8-1,3 (m, 8H), 0,91 (t, 3H)
IR (KBr) cm-1: 3400, 2980, 2940, 1760, 1730, 1640, 1610, 1530, 1510, 1485,
1442, 1370, 1240, 1220, 1200, 1180, 1080, 1020, 965, 705
UV-Spektrum:
λ max [nm] (280,0) 239,5
ε 14990 25860
Massenspektrum:
m/e 568, 316, 211Elemental analysis
C₃₇H₄₅ClN₄O₆, MW 677.26 g / mol
Ber. (%): C 65.6, H 6.69, N 8.3, Cl 5.2,
Found (%): C 65.6, H 6.89, N 8.1, Cl 5.4;
1 H-NMR (in CDCl₃)
δ (ppm) 7.3-6.41 (m, 13H), 4.25-3.9 (m, 4H), 3.8-3.3 (m, 8H), 2.48 (q, 2H) ), 2.33-2.21 (2a, 3H), 2.12-2.05 (2s, 3H) 1.8-1.3 (m, 8H), 0.91 (t, 3H)
IR (KBr) cm -1 : 3400, 2980, 2940, 1760, 1730, 1640, 1610, 1530, 1510, 1485, 1442, 1370, 1240, 1220, 1200, 1180, 1080, 1020, 965, 705
UV spectrum:
λ max [nm] (280.0) 239.5
ε 14990 25860
Mass spectrum:
m / e 568, 316, 211
Zu 600 mg (1,5 mmol) 1-[4-(2-[2-aminoethyl]-aminoethoxy)-phenyl]-1-(4-hydroxyphenyl)- 2-phenyl-but-1-en in 30 ml Dichlormethan und 5 ml Pyridin werden bei 0°C 470 mg (1,5 mmol) CNC-alanyl-hydroxysuccinimidester in Dichlormethan getropft. To 600 mg (1.5 mmol) 1- [4- (2- [2-aminoethyl] aminoethoxy) phenyl] -1- (4-hydroxyphenyl) - 2-phenyl-but-1-ene in 30 ml dichloromethane and 5 ml Pyridine is 470 mg (1.5 mmol) at 0 ° C CNC alanyl hydroxysuccinimide ester dropped in dichloromethane.
Nach beendeter Reaktion (ca. 1 h; DC-Kontrolle) werden noch 10 ml Essigsäureanhydrid zugegeben.After the reaction has ended (approx. 1 h; TLC control) 10 ml of acetic anhydride are added.
Nach 1 h wird die Reaktionsmischung mit eiskalter gesättigter NaHSO₄-Lösung sauer gestellt und zweimal mit Dichlormethan extrahiert. Die vereinigte organische Phase wird mit gesättigter NaHCO₃- und gesättigter NaCl-Lösung gewaschen, über Natriumsulfat getrocknet und einrotiert.After 1 h the reaction mixture is ice cold saturated NaHSO₄ solution acidified and twice with Extracted dichloromethane. The combined organic phase is with saturated NaHCO₃- and saturated NaCl solution washed, dried over sodium sulfate and evaporated.
Säulenchromatographie über Kieselgel (Dichlormethan/Methanol
= 30 : 1/d = 5 cm; 1 = 55 cm).
Ausbeute: 470 mg (45%) gelblichweißer, harziger Stoff
Fp: 70-73°C, sintert ab 50°C
Rf-Wert (Dichlormethan/Methanol = 30 : 1), 0,24Column chromatography on silica gel (dichloromethane / methanol = 30: 1 / d = 5 cm; 1 = 55 cm).
Yield: 470 mg (45%) yellowish white, resinous substance
Mp: 70-73 ° C, sinters from 50 ° C
R f (dichloromethane / methanol = 30: 1), 0.24
Elementaranalyse
C₃₆H₄₂ClN₅O₇, MW 692,23 g/mol
Ber. (%): C 62,5, H 6,12, N 10,1,
Gef. (%): C 61,8, H 6,23, N 9,7;
¹H-NMR (in CDCl₃):
δ (ppm) 7,45 (d, 1H), 7,3-6,45 (m, 13H), 4,52 (m, 1H),
4,3-4,05 (m, 4H), 3,85-3,35 (m, 8H),
2,48 (q, 2H), 2,33-2,21 (2s, 3H), 2,12-2,05
(2s, 3H), 1,5 (d, 3H), 0,91 (t, 3H)
IR (KBr) cm-1: 3330, 2980, 2940, 1755, 1730, 1680, 1635, 1610, 1510, 1490,
1444, 1370, 1240, 1220, 1200, 1080, 1020, 705
UV-Spektrum:
λ max [nm] (280,0) 239,5
ε 14360 24570
Massenspektrum:
m/e 625, 583, 316
Elemental analysis
C₃₆H₄₂ClN₅O₇, MW 692.23 g / mol
Ber. (%): C 62.5, H 6.12, N 10.1,
Found (%): C 61.8, H 6.23, N 9.7;
1 H-NMR (in CDCl₃):
δ (ppm) 7.45 (d, 1H), 7.3-6.45 (m, 13H), 4.52 (m, 1H), 4.3-4.05 (m, 4H), 3, 85-3.35 (m, 8H), 2.48 (q, 2H), 2.33-2.21 (2s, 3H), 2.12-2.05 (2s, 3H), 1.5 ( d, 3H), 0.91 (t, 3H)
IR (KBr) cm -1 : 3330, 2980, 2940, 1755, 1730, 1680, 1635, 1610, 1510, 1490, 1444, 1370, 1240, 1220, 1200, 1080, 1020, 705
UV spectrum:
λ max [nm] (280.0) 239.5
ε 14360 24570
Mass spectrum:
m / e 625, 583, 316
Zu 270 mg (0,7 mmol)
1-[4-(2-aminoethoxy)-phenyl]-1,2-diphenyl-but-1-en und 160 mg
(0,7 mmol) CNC-alanin in Dichlormethan werden bei 0°C 160 mg
(0,8 mmol) DCC gegeben. Nach 2 h (DC-Kontrolle) wird der
Dicyclohexylharnstoff abfiltriert, die Lösung einrotiert,
der Rückstand in Acetonitril aufgenommen, die Suspension
filtriert, einrotiert und mit Diethylether aufgeschäumt.
Säulenchromatographie über Kieselgel
(Dichlormethan/Ether/Petrolether = 2 : 1 : 1/d = 3 cm; 1 = 45 cm).
Ausbeute: 160 mg (41%) gelber, harziger Stoff
Fp: 51-55°C, sintert ab 42°C
Rf-Wert (Dichlormethan/Ether/Petrolether = 1 : 1 : 1): 0,37270 mg (0.7 mmol) of 1- [4- (2-aminoethoxy) phenyl] -1,2-diphenyl-but-1-ene and 160 mg (0.7 mmol) of CNC-alanine in dichloromethane are added to 0 ° C 160 mg (0.8 mmol) DCC added. After 2 h (TLC control), the dicyclohexylurea is filtered off, the solution is spun in, the residue is taken up in acetonitrile, the suspension is filtered, spun in and foamed with diethyl ether. Column chromatography on silica gel (dichloromethane / ether / petroleum ether = 2: 1: 1 / d = 3 cm; 1 = 45 cm).
Yield: 160 mg (41%) yellow, resinous substance
Mp: 51-55 ° C, sinters from 42 ° C
R f value (dichloromethane / ether / petroleum ether = 1: 1: 1): 0.37
Elementaranalyse
C₃₀H₃₃ClN₄O₄, MW 549,08 g/mol
Ber. (%): C 65,6, H 6,06, N 10,2, Cl 6,5,
Gef. (%): C 65,3, H 6,26, N 9,8, Cl 6,7;
¹H-NMR (in CDCl₃)
δ (ppm) 7,4-7,1 (2s, 10H), 6,9-6,45 (4H), 4,55 (m, 1H), 4,1
(t, 2H), 3,94 (t, 2H), 3,65 (t, 2H), 3,45 (t, 2H), 2,45 (q,
2H), 1,5 (d, 3H), 0,91 (t, 3H)
IR (KBr) cm-1: 3330, 2980, 2940, 1725, 1670, 1610, 1525, 1510, 1492, 1444,
1242, 1175, 1080, 969, 705
UV-Spektrum:
g max [nm] (276,1) 238,1
ε 18040 27950
Massenspektrum:
m/e 440, 300Elemental analysis
C₃₀H₃₃ClN₄O₄, MW 549.08 g / mol
Ber. (%): C 65.6, H 6.06, N 10.2, Cl 6.5,
Found (%): C 65.3, H 6.26, N 9.8, Cl 6.7;
1 H-NMR (in CDCl₃)
δ (ppm) 7.4-7.1 (2s, 10H), 6.9-6.45 (4H), 4.55 (m, 1H), 4.1 (t, 2H), 3.94 ( t, 2H), 3.65 (t, 2H), 3.45 (t, 2H), 2.45 (q, 2H), 1.5 (d, 3H), 0.91 (t, 3H)
IR (KBr) cm -1 : 3330, 2980, 2940, 1725, 1670, 1610, 1525, 1510, 1492, 1444, 1242, 1175, 1080, 969, 705
UV spectrum:
g max [nm] (276.1) 238.1
ε 18040 27950
Mass spectrum:
m / e 440, 300
Zu einer Lösung von 3,1 g (10,5 mmol) HECNU-hemisuccinat, 1,3 g (11 mmol) N-Hydroxysuccinimid und einer Spatelspitze DMAP in Dichlormethan werden bei 0°C 2,2 g (11 mmol) DCC zugegeben. Nach vollständiger Bildung des N-Hydroxysuccinimidesters (DC-Kontrolle) wird die Suspension zu 3,6 g (10 mmol) 1-[4-(2-aminoethoxy)-phenyl]-1-(4-hydroxyphenyl)-2-phenyl-but-1- en in Dichlormethan/Pyridin filtriert.To a solution of 3.1 g (10.5 mmol) of HECNU hemisuccinate, 1.3 g (11 mmol) N-hydroxysuccinimide and a spatula tip DMAP in dichloromethane are 2.2 g (11 mmol) DCC at 0 ° C admitted. After complete formation of the N-hydroxysuccinimide ester (DC control) becomes the suspension to 3.6 g (10 mmol) 1- [4- (2-aminoethoxy) phenyl] -1- (4-hydroxyphenyl) -2-phenylbut-1- filtered in dichloromethane / pyridine.
Nach 4 h wird eiskalte NaHSO₄-Lösung zugegeben. Nach
zweimaligen Extrahieren mit Dichlormethan wird die
organischen Phase mit gesättigter NaHCO₃- und dreimal mit
NaCl-Lösung gewaschen. Nach Trocknen über Natriumsulfat wird
einrotiert, der Rückstand in Acetonitril aufgenommen,
filtriert, einrotiert und mit Ether aufgeschäumt.
Säulenchromatographie über Kieselgel
(Dichlormethan/Methanol = 100 : 1-30 : 1/d = 5,5 cm; 1 = 55 cm).
Ausbeute: 4,3 g (67,5%) gelber, zähviskoser Stoff
Rf-Wert (Dichlormethan/Methanol = 20 : 1): 0,3
¹H-NMR (in CDCl₃):
δ (ppm) 7,465 (m, 1H), 7,19-6,45 (m, 13H), 6,05-5,97 (2t,
1H), 4,315-4,285 (2t 1 : 1, 2H), 4,16 (m, 2H), 4,1-4,04 (m,
2H), 3,91-3,54 (5m, 4H), 3,49 (m, 2H), 2,61 (m, 2H),
2,555-2,41 (m, 2H), 2,48 (q, 2H), 0,925-0,92 (2t, 3H)
After 4 h, ice-cold NaHSO₄ solution is added. After extracting twice with dichloromethane, the organic phase is washed with saturated NaHCO₃ and three times with NaCl solution. After drying over sodium sulfate, the mixture is evaporated in a rotary evaporator, the residue is taken up in acetonitrile, filtered, evaporated in a rotary evaporator and foamed with ether. Column chromatography on silica gel (dichloromethane / methanol = 100: 1-30: 1 / d = 5.5 cm; 1 = 55 cm).
Yield: 4.3 g (67.5%) of a yellow, viscous substance
R f value (dichloromethane / methanol = 20: 1): 0.3
1 H-NMR (in CDCl₃):
δ (ppm) 7.465 (m, 1H), 7.19-6.45 (m, 13H), 6.05-5.97 (2t, 1H), 4.315-4.285 (2t 1: 1, 2H), 4 , 16 (m, 2H), 4.1-4.04 (m, 2H), 3.91-3.54 (5m, 4H), 3.49 (m, 2H), 2.61 (m, 2H) ), 2.555-2.41 (m, 2H), 2.48 (q, 2H), 0.925-0.92 (2t, 3H)
Eine Lösung von 1,83 g (6 mmol) Chlorambucil, 799 mg (6,5
mmol) N-Hydroxysuccinimid und 1,34 g (6,5 mmol) DCC wird bei
0°C in Dichlormethan 2 h gerührt. Anschließend wird das
Gemisch zu einer Lösung von 2,93 g (6 mmol)
1-[4-(2-[6-aminohexyl]-aminoethoxy)-phenyl]-
1-(4-hydroxyphenyl)-2-(4-methoxyphenyl)-but-1-en in 30 ml
Triethylamin filtriert. Nach weiteren 2 h (DC-Kontrolle)
wird eiskalte NaHSO₄-Lösung zugegeben und dreimal mit
Dichlormethan extrahiert. Die vereinigte organische Phase
wird mit gesättigter NaHCO₃- und NaCl-Lösung gewaschen,
über Na₂SO₄ getrocknet und einrotiert.
Säulenchromatographie über Kieselgel (Dichlormethan/THF = 7,3
+ 0,5-2% Methanol/d = 6 cm, 1 = 55 cm)
Ausbeute: 2,63 g (57%) weißer, harziger Stoff
Fp: 55-58°C, sintert ab 50°C
Rf-Wert (Dichlormethan/Methanol = 9 : 1): 0,34A solution of 1.83 g (6 mmol) of chlorambucil, 799 mg (6.5 mmol) of N-hydroxysuccinimide and 1.34 g (6.5 mmol) of DCC is stirred at 0 ° C. in dichloromethane for 2 h. Then the mixture becomes a solution of 2.93 g (6 mmol) of 1- [4- (2- [6-aminohexyl] aminoethoxy) phenyl] -1- (4-hydroxyphenyl) -2- (4-methoxyphenyl ) -but-1-en filtered in 30 ml triethylamine. After a further 2 h (TLC control), ice-cold NaHSO₄ solution is added and extracted three times with dichloromethane. The combined organic phase is washed with saturated NaHCO₃ and NaCl solution, dried over Na₂SO₄ and evaporated.
Column chromatography on silica gel (dichloromethane / THF = 7.3 + 0.5-2% methanol / d = 6 cm, 1 = 55 cm)
Yield: 2.63 g (57%) white, resinous substance
Mp: 55-58 ° C, sinters from 50 ° C
R f value (dichloromethane / methanol = 9: 1): 0.34
Elementaranalyse
C₄₅H₅₇Cl₂N₃O₄, MW 774,89 g/mol
Ber. (%): C 69,8, H 7,41, N 5,4, Cl 9,2,
Gef. (%): C 69,9, H 7,68, N 5,2, Cl 9,3;
¹H-NMR (in CDCl₃):
δ (ppm) 7,2-6,4 (m, 16H), 5,65 (t, 1H), 4,2-3,9 (m, 2H),
3,73 (s, 3H), 3,64 (s, 8H), 3,3-2,9 (m, 4H), 2,8-2,35 (m, 6H)
2,2-2,0 (m, 2H), 2,0-1,8 (m, 2H), 1,7-1,2 (m, 8H), 0,91 (t,
3H)
IR (KBr) cm-1: 3300, 2940, 1645, 1610, 1510, 1460, 2440, 1360, 1240, 1175,
1035, 830.
UV-Spektrum:
λ max [nm] 289,1 252,6
ε 18510 36070
Massenspektrum:
m/e 774, 776, 778, 738Elemental analysis
C₄₅H₅₇Cl₂N₃O₄, MW 774.89 g / mol
Ber. (%): C 69.8, H 7.41, N 5.4, Cl 9.2,
Found (%): C 69.9, H 7.68, N 5.2, Cl 9.3;
1 H-NMR (in CDCl₃):
δ (ppm) 7.2-6.4 (m, 16H), 5.65 (t, 1H), 4.2-3.9 (m, 2H), 3.73 (s, 3H), 3, 64 (s, 8H), 3.3-2.9 (m, 4H), 2.8-2.35 (m, 6H) 2.2-2.0 (m, 2H), 2.0-1 , 8 (m, 2H), 1.7-1.2 (m, 8H), 0.91 (t, 3H)
IR (KBr) cm -1 : 3300, 2940, 1645, 1610, 1510, 1460, 2440, 1360, 1240, 1175, 1035, 830.
UV spectrum:
λ max [nm] 289.1 252.6
ε 18510 36070
Mass spectrum:
m / e 774, 776, 778, 738
Zu einer Lösung von 1,5 g (5 mmol) Melphalan in
Dichlormethan/Triethylamin werden bei 0°C 2 ml
Essigsäureanhydrid gegeben. Nach 1 h Rühren wird NaHCO₃-
Lösung zugegeben und weitere 2 h gerührt. Anschließend wird
mit gesättigter NaHSO₄-Lösung sauer gestellt und zweimal
mit Dichlormethan extrahiert. Die organische Phase wird mit
NaCl-Lösung gewaschen, über Natriumsulfat getrocknet und
einrotiert. Die so gewonnenen 1,15 g (3,2 mmol)
Acetylmelphalan werden in Dichlormethan gelöst und bei 0°C
mit 660 mg (3,5 mmol) DCC und 370 mg (3,5 mmol)
N-Hydroxysuccinimid umgesetzt. Nach beendeter Reaktion
(DC-Kontrolle) wird diese Suspension zu einer Lösung von
1,56 (3,2 mmol)
1-[4-(2-[6-aminohexyl]-aminoethoxy)-phenyl]-1-(4-hydroxyphenyl)-
2-(4-methoxyphenyl)-but-1-en (4OH-4′-OMe-HD-TAM) in
eiskaltem Dichlormethan/Triethylamin filtriert. Nach 2 h wird
eiskalte NaHSO₄-Lösung zugegeben. Anschließend wird
zweimal mit Dichlormethan extrahiert und die organische
Phase mit gesättigter NaHCO₃- und NaCl-Lösung gewaschen,
über Na₂SO₄ getrocknet und einrotiert.
Rohausbeute: 3,44 g
Säulenchromatographie über Kieselgel
(Dichlormethan/Methanol = 7 : 3/d = 4 cm, 1 = 10 cm)
Ausbeute: 2,7 g 4-OH-4′-OMe-HD-TAM-(N-acetyl-elphalan)amid,
leicht verunreinigt, aber das restliche 4-OH-4′-OMe-HD-TAM
kann abgetrennt werden.2 ml of acetic anhydride are added at 0 ° C. to a solution of 1.5 g (5 mmol) of melphalan in dichloromethane / triethylamine. After stirring for 1 h, NaHCO 3 solution is added and the mixture is stirred for a further 2 h. It is then acidified with saturated NaHSO₄ solution and extracted twice with dichloromethane. The organic phase is washed with NaCl solution, dried over sodium sulfate and evaporated. The 1.15 g (3.2 mmol) acetylmelphalan thus obtained are dissolved in dichloromethane and reacted at 0 ° C. with 660 mg (3.5 mmol) DCC and 370 mg (3.5 mmol) N-hydroxysuccinimide. After the reaction had ended (TLC control), this suspension became a solution of 1.56 (3.2 mmol) 1- [4- (2- [6-aminohexyl] aminoethoxy) phenyl] -1- (4-hydroxyphenyl ) - 2- (4-methoxyphenyl) -but-1-ene (4OH-4'-OMe-HD-TAM) filtered in ice-cold dichloromethane / triethylamine. After 2 h, ice-cold NaHSO₄ solution is added. It is then extracted twice with dichloromethane and the organic phase washed with saturated NaHCO₃- and NaCl solution, dried over Na₂SO₄ and evaporated.
Crude yield: 3.44 g
Column chromatography on silica gel (dichloromethane / methanol = 7: 3 / d = 4 cm, 1 = 10 cm)
Yield: 2.7 g of 4-OH-4'-OMe-HD-TAM- (N-acetyl-elphalan) amide, slightly contaminated, but the remaining 4-OH-4'-OMe-HD-TAM can be separated off.
Diese 2,7 g werden in Dichlormethan gelöst und nach Zugabe
von 3 ml Essigsäureanhydrid und 3 ml Triethylamin bei 0°C
gerührt. Nach beendeter Acetylierung (DC-Kontrolle) wird
NaHCO₃-Lösung zugegeben und weitere 2 h gerührt.
Anschließend wird mit gesättigter NaHSO₄ und NaCl-Lösung
gewaschen, über Natriumsulfat getrocknet und einrotiert.
Säulenchromatographie über Kieselgel
(Dichlormethan/Methanol/Petrolether = 76 : 4 : 20/d = 6 cm, 1 = 70 cm).
Ausbeute: 1,56 g (54%) weißer, harziger Stoff
Fp: 78-80°C, sintert ab 65°C
Rf-Wert (Dichlormethan/Methanol = 9 : 1): 0,57These 2.7 g are dissolved in dichloromethane and, after addition of 3 ml of acetic anhydride and 3 ml of triethylamine, stirred at 0 ° C. After the acetylation (DC control) has ended, NaHCO 3 solution is added and the mixture is stirred for a further 2 h. Then it is washed with saturated NaHSO₄ and NaCl solution, dried over sodium sulfate and evaporated. Column chromatography on silica gel (dichloromethane / methanol / petroleum ether = 76: 4: 20 / d = 6 cm, 1 = 70 cm).
Yield: 1.56 g (54%) white, resinous substance
Mp: 78-80 ° C, sinters from 65 ° C
R f value (dichloromethane / methanol = 9: 1): 0.57
Elementaranalyse
C₅₀H₆₂Cl₂N₄O₇, MW 901,97 g/mol
Ber. (%): C 66,6, H 6,93, N 6,2, Cl 7,9,
Gef. (%): C 66,5, H 7,18, N 6,1, Cl 7,9;
¹H-NMR (in CDCl₃):
δ (ppm) 7,22-6,51 (m, 16H), 4,55-4,48 (2m, 1H), 4,16-3,94
(m, 2H), 3,76-3,75 (2s, 3H), 3,73-3,59 (m, 8H), 3,51-2,87
(m, 8H), 2,44 (m, 2H), 2,31-1,96 (15s, 9H), 1,66-1,2 (m,
8H), 0,915 (m, 3H)
IR (KBr) cm-1: 3300, 2940, 1760, 1650, 1610, 1510, 1465, 1440, 1370, 1290,
1240, 1218, 1198, 1180. 1035, 840
UV-Spektrum:
g max [nm] 287,3 258,6
ε 16080 35420
Massenspektrum:
m/e 901, 903, 905Elemental analysis
C₅₀H₆₂Cl₂N₄O₇, MW 901.97 g / mol
Ber. (%): C 66.6, H 6.93, N 6.2, Cl 7.9,
Found (%): C 66.5, H 7.18, N 6.1, Cl 7.9;
1 H-NMR (in CDCl₃):
δ (ppm) 7.22-6.51 (m, 16H), 4.55-4.48 (2m, 1H), 4.16-3.94 (m, 2H), 3.76-3.75 (2s, 3H), 3.73-3.59 (m, 8H), 3.51-2.87 (m, 8H), 2.44 (m, 2H), 2.31-1.96 (15s , 9H), 1.66-1.2 (m, 8H), 0.915 (m, 3H)
IR (KBr) cm -1 : 3300, 2940, 1760, 1650, 1610, 1510, 1465, 1440, 1370, 1290, 1240, 1218, 1198, 1180. 1035, 840
UV spectrum:
g max [nm] 287.3 258.6
ε 16080 35420
Mass spectrum:
m / e 901, 903, 905
Zu einer Lösung von 3,6 g (6 mmol) 1-[4-(2-[N-carboxypentyl]-acetylaminoethoxy)phenyl]-1-(4- acetylphenyl)-2-(4-methoxyphenyl)-but-1-en in Dichlormethan bei 0°C werden 1,4 g (6,5 mmol) DCC und 750 mg (6,5 mmol) N-Hydroxysuccinimid gegeben. Nach 2 h wird diese Suspension zu einer Lösung von 1,6 g (6 mmol) Mustaminhydrochlorid in 10 ml Triethylamin filtriert.To a solution of 3.6 g (6 mmol) 1- [4- (2- [N-carboxypentyl] acetylaminoethoxy) phenyl] -1- (4- acetylphenyl) -2- (4-methoxyphenyl) but-1-ene in dichloromethane at 0 ° C 1.4 g (6.5 mmol) DCC and 750 mg (6.5 mmol) Given N-hydroxysuccinimide. After 2 h this suspension to a solution of 1.6 g (6 mmol) mustamine hydrochloride in Filter 10 ml of triethylamine.
Nach weiteren 2 h wird mit eiskalter NaHSO₄-Lösung sauer
gestellt und zweimal mit Dichlormethan extrahiert. Die
organische Phase wird mit gesättigter NaCl-Lösung gewaschen,
über Natriumsulfat getrocknet, einrotiert, der Rückstand in
Acetonitril aufgenommen, die Suspension filtriert und
einrotiert.
Rohausbeute: 3,7 g
Säulenchromatographie über Kieselgel (Dichlormethan/THF
= 85 : 15 + Methanol 0-2%/d = 6 cm, 1 = 70 cm)
Ausbeute: 820 mg (18%) farbloses zähviskoses Öl, ergibt beim
Einrotieren mit etherischer HCl einen blaßgelben, harzigen,
hygroskopischen Stoff
Fp: 53-59°C, sintert ab 48°C (Hydrochlorid)
Rf-Wert (Dichlormethan/Methanol = 9 : 1): 0,8
¹H-NMR (in CDCl₃):
δ (ppm) 7,3-6,4 (m, 12H), 4,2-3,9 (m, 2H), 3,77 (s, 3H),
3,55 (t, 4H), 3,47-3,15 (m, 4H), 2,9 (t, 4H), 2,68 (t, 2H),
2,5-1,9 (m, 12H), 1,8-1,2 (m, 6H), 0,91 (t, 3H)
IR-(KBr) cm-1: 3300, 2960, 1760, 1740, 1650, 1610, 1550, 1510, 1455, 1435,
1370, 1290, 1240, 1220, 1200, 1175, 1110, 1030, 1020, 840
UV-Spektrum:
λ max [nm] 285,1 239,2
ε 11370 15520
Massenspektrum:
m/e 754, 712.After a further 2 h, the mixture is acidified with ice-cold NaHSO₄ solution and extracted twice with dichloromethane. The organic phase is washed with saturated NaCl solution, dried over sodium sulfate, evaporated, the residue taken up in acetonitrile, the suspension filtered and evaporated.
Crude yield: 3.7 g
Column chromatography on silica gel (dichloromethane / THF = 85: 15 + methanol 0-2% / d = 6 cm, 1 = 70 cm)
Yield: 820 mg (18%) colorless, viscous oil, gives a pale yellow, resinous, hygroscopic substance when rotated in with ethereal HCl
Mp: 53-59 ° C, sinters from 48 ° C (hydrochloride)
R f value (dichloromethane / methanol = 9: 1): 0.8
1 H-NMR (in CDCl₃):
δ (ppm) 7.3-6.4 (m, 12H), 4.2-3.9 (m, 2H), 3.77 (s, 3H), 3.55 (t, 4H), 3, 47-3.15 (m, 4H), 2.9 (t, 4H), 2.68 (t, 2H), 2.5-1.9 (m, 12H), 1.8-1.2 ( m, 6H), 0.91 (t, 3H)
IR- (KBr) cm -1 : 3300, 2960, 1760, 1740, 1650, 1610, 1550, 1510, 1455, 1435, 1370, 1290, 1240, 1220, 1200, 1175, 1110, 1030, 1020, 840
UV spectrum:
λ max [nm] 285.1 239.2
ε 11370 15520
Mass spectrum:
m / e 754, 712.
0,5 mmol (264 mg) N-(Bisdesmethyltamoxifin)-1,4-dioxo-butyl-aminoethylaminoethylamin werden mit 0,5 mmol (207 mg) K₂PtCl₄ in 5 ml H₂O/DMF (1 : 1) gerührt. Nach 3 Tagen setzt sich ein Niederschlag ab. Dann werden 50 ml 5%ige KCl-Lösung zugesetzt. Der Niederschlag wird abgenutscht, mit 1NCHl und dann mit H₂O gewaschen. Das schwachgelbe Pulver wird über P₂O₅ getrocknet.0.5 mmol (264 mg) N- (bisdesmethyltamoxifin) -1,4-dioxo-butylaminoethylaminoethylamine are with 0.5 mmol (207 mg) K₂PtCl₄ in 5 ml H₂O / DMF (1: 1) stirred. After 3 days it starts Precipitation. Then 50 ml of 5% KCl solution added. The precipitate is filtered off with 1NCHl and then washed with H₂O. The pale yellow powder becomes over P₂O₅ dried.
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19893907290 DE3907290A1 (en) | 1989-03-07 | 1989-03-07 | STEROID HORMONE RECEPTOR AFFINES ANTITUARY ACTIVE SUBSTANCES |
PCT/EP1990/000344 WO1990010638A1 (en) | 1989-03-07 | 1990-03-02 | Antitumoral agents with an affinity for steroid hormone receptors |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19893907290 DE3907290A1 (en) | 1989-03-07 | 1989-03-07 | STEROID HORMONE RECEPTOR AFFINES ANTITUARY ACTIVE SUBSTANCES |
Publications (1)
Publication Number | Publication Date |
---|---|
DE3907290A1 true DE3907290A1 (en) | 1990-09-13 |
Family
ID=6375718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19893907290 Withdrawn DE3907290A1 (en) | 1989-03-07 | 1989-03-07 | STEROID HORMONE RECEPTOR AFFINES ANTITUARY ACTIVE SUBSTANCES |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE3907290A1 (en) |
WO (1) | WO1990010638A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0489220A1 (en) * | 1990-12-02 | 1992-06-10 | American Cyanamid Company | Cytotoxic N,N'-bis (succinyl-peptide-) derivatives of 1,4-bis (aminoalkyl)-5,8-dihydroxyanthraquinones and antibody conjugates thereof |
WO1995018141A1 (en) * | 1993-12-29 | 1995-07-06 | Iskra Industry Co., Ltd. | Medicinal composition for bone resorption inhibition and osteogenesis acceleration |
DE19831648A1 (en) * | 1998-07-15 | 2000-01-27 | Stiebel Eltron Gmbh & Co Kg | Process for automatic adaptation of control electronics of a gas heater device so that emissions are minimized by ensuring that the Lambda value is greater than one |
DE10012120A1 (en) * | 2000-03-13 | 2001-09-27 | Ktb Tumorforschungs Gmbh | New ligand, comprising therapeutic or diagnostic agent bonded non-covalently with substance having high affinity to transport molecule |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6803494A (en) * | 1993-06-07 | 1995-01-03 | British Technology Group Limited | Anticancer compounds |
JPH07101977A (en) * | 1993-10-05 | 1995-04-18 | Kureha Chem Ind Co Ltd | New estradiol derivative with reduced hormone action and growth factor inhibitor thereof |
WO1998051702A1 (en) * | 1997-05-14 | 1998-11-19 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for destruction of selected proteins |
US8063249B1 (en) | 2008-04-25 | 2011-11-22 | Olema Pharmaceuticals, Inc. | Substituted triphenyl butenes |
PE20181083A1 (en) | 2015-05-29 | 2018-07-05 | Eisai Randd Man Co Ltd | TETRASUSTITUTED ALKENE COMPOUNDS AND THEIR USE |
WO2018097273A1 (en) | 2016-11-28 | 2018-05-31 | Eisai R&D Management Co., Ltd. | Salts of indazole derivative and crystals thereof |
CN113811333B (en) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | Compounds targeting anti-cancer nuclear hormone receptors |
TW202131930A (en) | 2019-11-13 | 2021-09-01 | 美商諾維雪碧歐公司 | Anti-cancer nuclear hormone receptor-targeting compounds |
EP4313991A1 (en) | 2021-03-23 | 2024-02-07 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2201419A (en) * | 1987-02-24 | 1988-09-01 | Erba Farmitalia | Anthracycline-oestrone derivatives |
-
1989
- 1989-03-07 DE DE19893907290 patent/DE3907290A1/en not_active Withdrawn
-
1990
- 1990-03-02 WO PCT/EP1990/000344 patent/WO1990010638A1/en unknown
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0489220A1 (en) * | 1990-12-02 | 1992-06-10 | American Cyanamid Company | Cytotoxic N,N'-bis (succinyl-peptide-) derivatives of 1,4-bis (aminoalkyl)-5,8-dihydroxyanthraquinones and antibody conjugates thereof |
WO1995018141A1 (en) * | 1993-12-29 | 1995-07-06 | Iskra Industry Co., Ltd. | Medicinal composition for bone resorption inhibition and osteogenesis acceleration |
US5698542A (en) * | 1993-12-29 | 1997-12-16 | Iskra Industry Co., Ltd. | Bone resorption inhibition/osteogenesis promotion pharmaceutical composition |
DE19831648A1 (en) * | 1998-07-15 | 2000-01-27 | Stiebel Eltron Gmbh & Co Kg | Process for automatic adaptation of control electronics of a gas heater device so that emissions are minimized by ensuring that the Lambda value is greater than one |
DE10012120A1 (en) * | 2000-03-13 | 2001-09-27 | Ktb Tumorforschungs Gmbh | New ligand, comprising therapeutic or diagnostic agent bonded non-covalently with substance having high affinity to transport molecule |
Also Published As
Publication number | Publication date |
---|---|
WO1990010638A1 (en) | 1990-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3907290A1 (en) | STEROID HORMONE RECEPTOR AFFINES ANTITUARY ACTIVE SUBSTANCES | |
RU2137755C1 (en) | Conjugates: therapeutic compound-fatty acid | |
DE69533615T2 (en) | Anthracycline prodrugs, process for their preparation and their use in selective chemotherapy | |
EP0624595A2 (en) | Nor-derivation of bile-acids, a process for their production and their use as medicines | |
EP0573848A2 (en) | Bile-acid derivatives, a process for their production and their use as medicines | |
EP0648778A2 (en) | 11-Benzaldoximeestradiene-derivates, a process for their preparation and pharmaceutical compositions containing them | |
DE4141746A1 (en) | 20-METHYL-SUBSTITUTED VITAMIN D DERIVATIVES | |
Paschke et al. | Novel spacer linked bile acid–cisplatin compounds as a model for specific drug delivery, synthesis and characterization | |
EP1747230A1 (en) | Aminosulphonyl-or aminosulphonylamino-substituted phenyl esters as estradiol prodrugs | |
US4213978A (en) | Anti-acne and anti-seborrhea prodrug derivatives of progesterone | |
EP0060999B1 (en) | Galactopyranosides, process for their preparation and their use as antigens or immuno absorbents | |
WO1994022491A1 (en) | Bifunctional chelators and their use in radiopharmaceuticals | |
EP0072531A1 (en) | Derivatives of cyclophosphamide, process for their preparation and their use | |
WO1990009373A1 (en) | Hydroxyalkane carboxylic acid derivates, their manufacture and use | |
DE2733867B2 (en) | Oleandomycin derivatives and antibacterial agents containing these compounds | |
DE4308095A1 (en) | Prodrug derivatives of pharmaceutical agents with hydroxyl groups, process for their preparation and their use | |
DE60123105T2 (en) | A process for producing 4'-O-substituted 4'-demethyl-1-deoxypodophyllotoxin derivatives and geometric isomers thereof, and anticancer preparation containing the same | |
EP0013891B1 (en) | Dipeptides for use in the treatment of diseases, some compounds of this class, medicaments containing dipeptides and their manufacture | |
EP1603930B1 (en) | Protein-bound derivatives of platinum complexes containing cyclobutane 1.1-dicarboxyllate ligands | |
Giniyatullina et al. | Synthesis of aminopropylamino derivatives of betulinic and oleanolic acids | |
DE2517293C2 (en) | Novel cardenolide β-glycosides, their preparation and uses | |
WO1996008505A1 (en) | Steroid esters and amides, method for their preparation and their pharmaceutical use | |
EP0089693B1 (en) | Steroid esters of n-(2-halogen-ethyl)-n-nitroso-carbamoyl amino acids and their peptides, and process for their preparation | |
EP0273439A2 (en) | Process for the preparation of lipophilic amino acid derivatives, and lipophilic amino acid derivatives | |
CH631997A5 (en) | Process for the preparation of novel derivatives of 9-chloro-prednisolone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8139 | Disposal/non-payment of the annual fee |